Interactions between the sympathetic and renin-angiotensin systems;INTERACTIONS DES SYSTEMES SYMPATHIQUE ET RENINE-ANGIOTENSINE

Therapie

Volumn 53, Issue 3, 1998, Pages 245-252

  K Laflamme, A ^a   De Champlain, J ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Heart failure; Hypertension; Renin angiotensin system; Sympathetic nervous system

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR; PHENYLEPHRINE;

ADRENERGIC SYSTEM; ADRENERGIC TRANSMISSION; BLOOD VESSEL TONE; CARDIOVASCULAR SYSTEM; ENDOTHELIUM; HEART FAILURE; HUMAN; HYPERTENSION; NERVE ENDING; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; ANIMAL; METABOLISM; PERIPHERAL NERVOUS SYSTEM;

ANIMALS; HUMANS; PERIPHERAL NERVOUS SYSTEM; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM;

EID: 0031820232     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Reid IA. Interactions between Ang II, sympathetic nervous system, and baroreflexes in regulation of blood pressure. Am J Physiol 1992; 262: E763-E778.
2. Saxena PR. Interaction between the renin-angiotensin-aldosterone and sympathetic nervous systems. J Cardiovasc Pharmacol 1992; 19 (suppl.6): S80-S86.
3. Zanchetti AS. Neural regulation of renin release: experimental-evidence and clinical implications in arterial-hypertension. Circulation 1977; 56: 691-698.
4. Davis JO, Freeman RH. Mechanisms regulating renin release. Physiol Rev 1976; 56: 1-56.
5. Taddei S, Virdis A, Mattei P et al. Vascular renin-angiotensin system and sympathetic nervous system activity in human hypertension. J Cardiovasc Pharmacol 1994; 23: S9-S14.
6. Bishop VS, Haywood JR. Hormonal control of cardiovascular reflexes. In: Zucker IH, Gilmore JP, eds. Reflex Control of the Circulation. Boca Raton, FL: CRC, 1991: 253-271.
7. Liard JF. The baroreceptor reflexes in experimental hypertension. Clin Exp Hypertens 1980; 2: 479-498.
8. Guo GB, Abboud FM. Angiotensin II attenuates baroreceptor control of heart rate and sympathetic activity. Am J Physiol 1984; 246: H80-H89.
9. Goldsmith SR, Hasking GJ. Effect of a pressor infusion of angiotensin II on sympathetic activity and heart rate in normal humans. Circ Res 1991; 68: 263-268.
10. Kawano Y, Yoshida K, Matsuoka H, Omae T. Chronic effects of central and systemic administration of losartan on blood pressure and baroreceptor reflex in spontaneously hypertensive rats. Am J Hypertens 1994; 7: 536-542.
11. Unger T, Badoer E, Ganten D et al. Brain angiotensin: pathways and pharmacology. Circulation 1988; 77 (suppl 77): 140-154.
12. Ferguson AV, Bains JS. Actions of angiotensin in the subfornical organ and area postrema: implications for long term control of autonomic output. Clin Exp Pharmacol Physiol 1997; 24: 96-101.
13. Matsukawa S, Reid IA. Role of the area postrema in the modulation of the baroreflex control of heart rate by angiotensin II. Circ Res 1990; 67: 1462-1473.
14. Fink GD, Bruner CA, Mangiapane MI. Area postrema is critical for angiotensin-induced hypertension in rats. Hypertension 1987; 9: 355-361.
15. Cox BF, Bishop VS. Neural and humoral mechanisms of angiotensin-dependent hypertension. Am J Physiol 1991; 261: H1284-H1291.
16. Andrews CO, Crim JW, Hartle DK. Angiotensin II binding in area postrema and nucleus tractus solitarius of SHR and WKY rats. Brain Res Bull 1993; 32: 419-424.
17. Townend JN, Al-Ani M, West JN et al. Modulation of cardiac autonomic control in humans by angiotensin II. Hypertension 1995; 25: 1270-1275.
18. Lumbers ER, McCloskey DI, Potter EK. Inhibition by angiotensin II of baroreceptor-evoked activity in cardiac vagal efferent nerves in the dog. J Physiol (Lond) 1979; 294: 69-80.
19. Potter EK. Angiotensin inhibits action of vagus nerve at the heart. Br J Pharmacol 1982; 75: 9-11.
20. Campbell BC Sturani A, Reid JL. Evidence of parasympathetic activity of the angiotensin converting enzyme inhibitor, captopril, in normotensive man. Clin Sci 1985; 68: 49-56.
21. Osterziel KJ, Dietz R, Schinid W et al. ACE inhibition improves vagal reactivity in patients with heart failure. Am Heart J 1990; 120: 1120-1129.
22. Bartholomeusz B, Widdop RE. Effect of acute and chronic treatment with the angiotensin II subtype I receptor antagonist EXP3174 on baroreflex function in conscious spontaneously hypertensive rats. J Hypertens 1995; 13: 219-225.
23. de Champlain J, Yacine A, Leblanc R et al. Effects of trandolapril on the sympathetic tone and reactivity in systemic hypertension. Am J Cardiol 1994; 73: 18C-25C.
24. K-Laflamme A, Oster L, Cardinal R, de Champlain J. Effects of renin-angiotensin blockade on sympathetic reactivity and β-adrenergic pathway in the spontaneously hypertensive rat. Hypertension 1997; 30: 278-287.
25. Niederberger M, Aubert JF, Nussberger J et al. Sympathetic nerve activity in conscious renal hypertensive rats treated with an angiotensin converting enzyme inhibitor or an angiotensin II antagonist. J Hypertens 1995; 13: 439-445.
26. de Champlain J. Pre- and postsynaptic adrenergic dysfunctions in hypertension. J Hypertens 1990; 8 (suppl 7): 577-585.
27. Wong PC, Hart SD, Zaspel AM et al. Functional studies of nonpeptide angiotensin II receptor subtype-specific ligands: DuP 753 (All-1) and PD123177 (All-2). J Pharmacol Exp Ther 1990; 255: 584-592.
28. 3H]-norepinephrine release from isolated atria of Wistar-Kyoto and spontaneously hypertensive rats. Am J Hypertens 1996; 9: 61-69.
29. Khairallah PA. Action of angiotensin on adrenergic nerve endings: inhibition of norepinephrine uptake. Federation Proc 1972; 31: 1351-1357.
30. Peach MJ Bumpus FM, Khairallah PA. Inhibition of norepinephrine uptake in hearts by angiotensin II and analog. J Pharmacol Exp Ther 1969; 167: 291-299.
31. Roth RH. Action of angiotensin on adrenergic nerve endings: enhancement of norepinephrine biosynthesis. Federation Proc 1972: 31: 1358-1364.
32. Lefkowitz RJ, Caron MG. Adrenergic-receptors: molecular mechanisms of clinically relevant regulation. Clin Res 1985; 33: 395-406.
33. Oster L, K-Laflamme A, Foucart S, de Champlain J. Losartan improves endothelial functions of mesenteric arteries in three experimental models of hypertension. Hypertension 1995; 25: 1360.
34. Horn E, Corwin SJ, Steinberg SF et al. Reduced lymphocyte stimulatory guanine nucleotide regulatory protein and β-adrenergic receptors in congestive heart failure and reversal with angiotensin converting enzyme inhibitor therapy. Circulation 1988; 78: 1373-1379.
35. Gilbert EM, Sandoval A, Larrabee P et al. Effect of lisinopril on cardiac adrenergic drive and myocardial β-receptor density in heart failure. Circulation 1988; 78 (suppl. II): 11-576.
36. 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev 1991; 43(2): 203-242.
37. Nguyen CT, de Champlain J, Bouvier M. Tissue specific changes in β-adrenergic receptors subtypes in DOCA-Salt hypertensive rats. Biomed J 1995; 2: 34-42.
38. 2-adrenoceptor density in heart, lung and kidney of spontaneously hypertensive rats.J Auton Pharmacol 1987; 7: 41-51.
39. Yamada S, Ishima T, Tomita T et al. Alterations in cardiac alpha and beta adrenoceptors during the development of spontaneous hypertension. J Pharmacol Exp Ther 1984; 228: 454-460.
40. van Zwieten PA, de Jonge A, Interaction between the adrenergic and renin-angiotensin-aldosterone systems. Postgrad Med J 1986; 62 (suppl 1): 23-27.
41. Madwed JB, Winquist RJ. Effects of losartan (DUP 753) and enalaprilat on the mean arterial pressure response to phenylephrine. J Hypertens 1994; 12: 159-162.
42. Qiu HY, Henrion D, Levy BI. Endogenous angiotensin II enhances phenylephrine-induced tone in hypertensive rats. Hypertension 1994; 24: 317-321.
43. Laher I, Thompson LP, Gagne L. Protein kinase C as a modulator of response amplification in vascular smooth muscle. Blood Vessels 1990, 27: 333-340.
44. Cachofeiro V, Maeso R, Rodrigo E et al. Nitric oxide and prostaglandins in the prolonged effects of losartan and ramipril in hypertension. Hypertension 1995; 26: 236-243.
45. Maeso R, Navarro-Cid J, Munoz-Garcia R et al. Losartan reduces phenylephrine constrictor response in aortic rings from spontaneously hypertensive rats. Role of nitric oxide and angiotensin II type 2 receptors. Hypertension 1996; 28: 967-972.
46. Laursen JB, Rajagopalan S, Galis Z et al. Role of Superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 1997; 95: 588-593.
47. Rajagopalan S, Kurz S, Münzel T et al. Angiotensin II-mediated hypertension in the rat increases vascular Superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996; 97: 1916-1923.
48. Cardillo C, Kilcoyne CM, Quyyumi AA et al. Decreased vasodilator response to isoproterenol during nitric oxide inhibition in humans. Hypertension 1997; 30: 918-921.
49. ATP channels and nitric oxide in conscious dogs. Circulation 1997; 95: 1568-1576.
50. Brady AJB, Warren JB, Poole-Wilson PA et al. Nitric oxide attenuates cardiac myocyte contraction. Am J Physiol 1993; 265: H176-H182.
51. Mohan P, Brutsaert DL, Paulus WJ, Sys SU. Myocardial contractile response to nitric oxide and cGMP. Circulation 1996; 93: 1223-1229.
52. Ikeda U, Yoshikazu M, Kawahara Y et al. Angiotensin II augments cytokine-stimulated nitric oxide synthesis in rat cardiac myocytes. Circulation 1995; 92: 2683-2689.
53. Crawford KW, Frey EA, Cote TE. Angiotensin II receptor recognized by DUP 753 regulates two distinct guanine nucleotide-binding protein signaling pathways. Mol Pharmacol 1991; 41: 154-162.
54. Gomez Llambi H, Manni F, LaPadula P et al. Myocardial contractility is modulated by angiotensin II via nitric oxide. Hypertension 1996; 27: 704-708.
55. K-Laflamme A, Foucart S, Moreau P et al. Sympathetic functions in N -nitro-L-arginine-methyl-ester-induced hypertension: modulation by the renin-angiotensin system. J Hypertens 1998; 16: 63-76.